Responses

Download PDFPDF
Extended report
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors
    • Xavier Mariette, Rheumatologist
    • Other Contributors:
      • Alan Reynolds, Paul Emery

    Dear Editor,

    Dear Editor,

    We recently published a meta-analysis of malignancy rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors (TNF-I). [1] Whilst there was no increase in the rates of all-site malignancy or lymphoma, there was an increased risk of non-melanoma skin cancer (NMSC) (1.45, 95% CI 1.15 to 1.76).

    The skin cancer analysis incl...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Non-melanoma skin cancer risk in patients with rheumatoid arthritis on tumor necrosis factor inhibitors

    Dear Editor,

    We read with interest the meta-analysis of registries and prospective observational studies conducted by Mariette and colleagues on the risk of malignancies in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) antagonists. (1) Their meta-analysis highlights the complexity surrounding this important clinical issue, when TNF antagonists are considered for patients with RA with...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Association of malignancies with tumour necrosis factor inhibitors: real facts
    • Srijit Das, Lecturer
    • Other Contributors:
      • Sakthiswary Rajalingham

    Dear Editor,

    We read with much interest the published article entitled 'Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis' by Mariette et al [1]. Beyond any doubt, autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus and psoriatic arthritis are associated with higher incidence of maligna...

    Show More
    Conflict of Interest:
    None declared.